Clinical data | |
---|---|
Trade names | Edronax, others |
Pregnancy category |
|
Routes of administration | By mouth (tablets) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ≥94%[2][3] |
Protein binding | 97–98%[2][3] |
Metabolism | Liver (CYP3A4-mediated)[2] |
Elimination half-life | 12–12.5 hours[2][3] |
Excretion | Urine (78%; 9–10% unchanged)[2][3] |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII |
|
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H23NO3 |
Molar mass | 313.397 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemate |
| |
| |
(what is this?) (verify) |
Reboxetine, sold under the brand name Edronax among others, is a drug of the norepinephrine reuptake inhibitor (NRI) class, marketed as an antidepressant by Pfizer for use in the treatment of major depression, although it has also been used off-label for panic disorder and attention deficit hyperactivity disorder (ADHD).[4] It is approved for use in many countries worldwide, but has not been approved for use in the United States. Although its effectiveness as an antidepressant has been challenged in multiple published reports, its popularity has continued to increase[dubious – discuss].[5]
{{cite book}}
: |work=
ignored (help)